陇神戎发(300534) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 51,307,797.47, representing a year-on-year increase of 21.04%[8] - Net profit attributable to shareholders was CNY -2,599,176.55, a significant decrease of 6,070.40% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -2,661,168.92, down 57.81% year-on-year[8] - The basic earnings per share was CNY -0.0086, a decrease of 6,070.40% compared to the same period last year[8] - Operating profit decreased by 31.81% year-on-year, mainly due to increased expenses and decreased investment income.[20] - Net profit decreased by 37.26% year-on-year, primarily due to a decline in total profit and increased non-operating expenses.[20] - Total profit decreased by 34.6% year-on-year, influenced by increased expenses and decreased investment income.[20] - The company reported a net profit of CNY 160,740,309.66, up from CNY 159,057,999.37, reflecting a growth of about 1.1%[39] - Net profit for the current period was -¥1,772,007.96, a significant decline from -¥42,123.28 in the previous period[42] - The company reported a total profit loss of -¥1,792,320.23, compared to a profit of ¥630,291.58 in the previous period[42] - Net profit for the period was ¥6,674,180.36, a decrease of 37.5% from ¥10,638,257.63 in the same period last year[50] - The total profit for the period was ¥8,251,682.68, down 34.5% from ¥12,616,379.88 in the previous year[50] Assets and Liabilities - Total assets increased by 3.77% to CNY 807,895,941.77 compared to the end of the previous year[8] - Current liabilities rose to CNY 73,202,155.66, compared to CNY 51,816,721.34, marking an increase of about 41.1%[33] - Non-current assets totaled CNY 519,071,775.46, up from CNY 504,858,287.20, reflecting a growth of approximately 2.4%[32] - The company's total liabilities increased to CNY 77,950,322.33 from CNY 57,683,888.01, indicating a rise of around 35%[33] - The total equity attributable to shareholders reached CNY 723,241,006.59, compared to CNY 720,830,596.10, showing a slight increase of about 0.3%[34] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY -11,082,457.14, an increase of 41.55% compared to the same period last year[8] - Cash flow from operating activities increased by 41.55% year-on-year, mainly due to increased cash received from sales and reduced tax payments.[20] - Cash flow from investing activities decreased by 109.36% year-on-year, primarily due to increased cash payments for investments and fixed asset construction.[20] - Cash flow from financing activities increased by 509.4% year-on-year, mainly due to increased cash received from short-term loans.[20] - The net cash flow from operating activities was -11,963,573.32 yuan, compared to -12,864,288.75 yuan in the previous period, indicating a slight improvement[62] - Total cash inflow from operating activities was 100,647,790.11 yuan, down from 146,136,717.02 yuan year-on-year, reflecting a decrease of approximately 31.2%[62] - Cash outflow from operating activities totaled 112,611,363.43 yuan, compared to 159,001,005.77 yuan in the previous period, showing a reduction of about 29.2%[62] - The net cash flow from investment activities was -19,661,506.20 yuan, worsening from -15,652,061.25 yuan in the previous period[62] - The net cash flow from financing activities was -3,421,640.85 yuan, compared to -4,032,139.42 yuan in the previous period, indicating an improvement[63] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,533[12] - The largest shareholder, Gansu State-owned Assets Investment Group Co., Ltd., held 26.55% of the shares, totaling 80,527,142 shares[12] - Gansu Guotou became the controlling shareholder of the company, holding 37.49% of the shares after the transfer of 26.10% equity from Northwest Yongxin Group Co., Ltd.[21] Other Financial Metrics - Cash and cash equivalents decreased by 43.38% compared to the beginning of the period, primarily due to cash payments for the construction of the "200 billion modern Chinese medicine production line expansion project (Phase II)" and the acquisition of 51% equity in Lanzhou Sanyuan Pharmaceutical Co., Ltd.[19] - Accounts receivable decreased by 65.43% compared to the beginning of the period, mainly due to the maturity and payment of acceptance bills used for project payments.[19] - Prepayments increased by 441.95% compared to the beginning of the period, primarily due to increased prepayments for the "200 billion modern Chinese medicine production line expansion project (Phase II)" construction.[19] - Cash and cash equivalents decreased to CNY 29,917,565.30 from CNY 55,276,186.26, a decline of approximately 46%[36] - Accounts receivable increased to CNY 167,357,192.75 from CNY 158,860,338.36, representing a growth of about 5.9%[36] - Inventory rose to CNY 35,795,959.34 from CNY 32,304,526.04, indicating an increase of approximately 10.5%[36] - Deferred income decreased to CNY 4,748,166.67 from CNY 5,867,166.67, a decline of approximately 19%[38] - Research and development expenses were ¥1,197,052.96, slightly down from ¥1,356,494.73 in the previous period[41] - Other income decreased to ¥399,999.96 from ¥1,873,000.00, indicating a decline of approximately 78.7%[41] - The company experienced a significant increase in management expenses, rising to ¥5,572,215.16 from ¥4,079,046.45, an increase of about 36.7%[41] - The financial expenses showed a notable change, with a current period expense of ¥30,083.66 compared to a gain of -¥102,330.77 in the previous period[41]